TEL AVIV, Israel, April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2–May 4, 2023. Chemomab management will present a corporate overview on Wednesday, May 3, 2023.
Aegis 2023 Virtual Investor Conference
Date: | May 3, 2023 |
Time: | 9:00am EDT |
Venue: | Virtual |
Format: | Webcast -- Corporate overview |
Presenter: | Senior management |
Webcast Link: | |
Information: | This email address is being protected from spambots. You need JavaScript enabled to view it. |
In addition, Chemomab reported that its corporate development team will be in Boston June 5-8, 2023, participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.
About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com.
Contacts: | |
Investors: | Investors & Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1 (917) 734-7387 | Consulting Vice President, Investor & Public Relations |
This email address is being protected from spambots. You need JavaScript enabled to view it. | Strategic Communications |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$1.13 |
| Daily Change: | -0.01 -0.88 |
| Daily Volume: | 219,573 |
| Market Cap: | US$21.650M |
May 15, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
